We are live on ! Find out more
ANIK icon

Anika Therapeutics

160 hedge funds and large institutions have $483M invested in Anika Therapeutics in 2014 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 56 increasing their positions, 57 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 15

19% more capital invested

Capital invested by funds: $405M → $483M (+$77.5M)

5% more funds holding

Funds holding: 153160 (+7)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

2% less repeat investments, than reductions

Existing positions increased: 56 | Existing positions reduced: 57

45% less call options, than puts

Call options by funds: $1.89M | Put options by funds: $3.46M

Holders
160
Holders Change
+7
Holders Change %
+4.58%
% of All Funds
4.27%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
25
Increased
56
Reduced
57
Closed
15
Calls
$1.89M
Puts
$3.46M
Net Calls
-$1.56M
Net Calls Change
-$368K
Name Holding Trade Value Shares
Change
Change in
Stake
Wellington Management Group
1
Wellington Management Group
Massachusetts
$34.2M +$12.6M +322,897 +62%
BFA
2
BlackRock Fund Advisors
California
$33.9M +$2.93M +74,972 +10%
Dimensional Fund Advisors
3
Dimensional Fund Advisors
Texas
$32.7M -$5.7M -145,864 -15%
BTW
4
Boston Trust Walden
Massachusetts
$29.1M +$12.3M +315,733 +79%
TSW
5
Thompson Siegel & Walmsley
Virginia
$26.8M +$2.38M +60,788 +10%
Vanguard Group
6
Vanguard Group
Pennsylvania
$26.6M +$1.63M +41,791 +7%
BIT
7
BlackRock Institutional Trust
California
$22.2M +$485K +12,420 +2%
RIM
8
Ranger Investment Management
Texas
$16.8M +$15.4M +394,200 +2,287%
Allianz Asset Management
9
Allianz Asset Management
Germany
$15.1M -$616K -15,758 -4%
GAM
10
Gotham Asset Management
New York
$14.1M -$1.12M -28,566 -8%
PCM
11
Portolan Capital Management
Massachusetts
$12.6M +$2.16M +55,298 +22%
State Street
12
State Street
Massachusetts
$12M +$135K +3,466 +1%
AAM
13
AMI Asset Management
California
$11.1M +$1.49M +38,137 +16%
Bank of New York Mellon
14
Bank of New York Mellon
New York
$9.97M +$344K +8,809 +4%
AQR Capital Management
15
AQR Capital Management
Connecticut
$9.13M +$2.44M +62,529 +39%
Renaissance Technologies
16
Renaissance Technologies
New York
$8.67M -$2.26M -57,800 -21%
Northern Trust
17
Northern Trust
Illinois
$7.31M -$182K -4,655 -3%
BA
18
BlackRock Advisors
Delaware
$6.98M +$71.9K +1,840 +1%
Millennium Management
19
Millennium Management
New York
$6.93M -$8.04M -205,733 -55%
Charles Schwab
20
Charles Schwab
California
$6.07M +$1.33M +33,962 +30%
OAM
21
Oxford Asset Management
United Kingdom
$5.99M +$2.5M +63,945 +77%
LCP
22
Lombardia Capital Partners
California
$5.73M +$5.5M +140,662 New
TA
23
Teachers Advisors
New York
$5.06M +$611K +15,627 +14%
TCIM
24
TIAA CREF Investment Management
New York
$4.33M -$119K -3,050 -3%
American Century Companies
25
American Century Companies
Missouri
$4.28M +$704 +18 +0%

ANIK Hedge Fund Activity: Q4 2014 in Review

160 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Anika Therapeutics (ANIK) for Q4 2014, worth a combined $483M — up 19% from $405M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new ANIK positions and 15 closed out — a net gain of 10 holders — while 56 added to existing stakes and 57 trimmed.

The largest buyer was Ranger Investment Management, adding an estimated $15.4M. The largest seller was Millennium Management, cutting an estimated $8.04M.

  • 160 institutional investors held Anika Therapeutics (ANIK) as of Q4 2014, up from 153 in Q3 2014.
  • Funds reported $483M of Anika Therapeutics stock for Q4 2014, up 19% quarter-over-quarter.
  • 25 funds opened new Anika Therapeutics positions in Q4 2014 and 15 closed out, a net change of +10 holders.
  • The largest Anika Therapeutics buyer in Q4 2014 was Ranger Investment Management, an estimated $15.4M added.
  • The largest Anika Therapeutics seller in Q4 2014 was Millennium Management, an estimated $8.04M sold.

Based on aggregated 13F filings for Q4 2014.